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Abstract
Background: Bronchiectasis (BE) is a chronic structural lung disease with frequent exacerbations, some of which
require hospital admission though no clear associated factors have been identified. We aimed to evaluate factors
associated with hospitalization due to exacerbations during a 1-year follow-up period.
Methods: A prospective observational study was performed in patients recruited from specialized BE clinics. We
considered all exacerbations diagnosed and treated with antibiotics during a follow-up period of 1 year. The protocol
recorded baseline variables, usual treatments, Bronchiectasis Severity Index (BSI) and FACED scores, comorbid
conditions and prior hospitalizations.
Results: Two hundred and 65 patients were recruited, of whom 162 required hospital admission during the follow-up
period. Independent risk factors for hospital admission were age, previous hospitalization due to BE, use of proton
pump inhibitors, heart failure, FACED and BSI, whereas pneumococcal vaccination was a protective factor. The area
under the receiver operator characteristic curve (AUC) was 0.799 for BSI model was 0.799, and 0.813 for FACED model.
Conclusions: Previous hospitalization, use of proton pump inhibitors, heart failure along with BSI or FACED scores is
associated factors for developing exacerbations that require hospitalization. Pneumococcal vaccination was protective.
This information may be useful for the design of preventive strategies and more intensive follow-up plans.
Background
Bronchiectasis (BE) is a chronic structural respiratory
disease characterized by dilated bronchi that courses
with exacerbations that may require hospital admission
[1, 2]. Although the incidence of BE is not well known,
the average annual age-adjusted hospitalization rate was
reported to be around 9.4 hospitalizations per 100,000
population in Germany, [3] and 16.5 in the United States
[4]. Hospitalizations were higher among women and in
the >60 year age group, though no clear predictors of
hospital needs were identified. The average rate of
exacerbations per year varies widely among patients and
the causes remain unknown.
Exacerbations may lead to deterioration of lung
function, [5] poor prognosis [6] and increased mortality
[4, 7] and costs, [8] as in patients with other chronic
respiratory diseases [9, 10]. In general, patients with ad-
vanced phases of disease and high Bronchiectasis Severity
Index (BSI) or FACED scores have an average of two or
more exacerbations per year [11], and the trend towards
longer hospital stays [4, 12].
Few data are available on risk factors and patient
characteristics in BE that might provoke exacerbations
requiring hospital admission [13] apart from severity
scales. This information may be useful for promoting
strategies to prevent hospitalization and for personalized
patient monitoring and management. Exacerbations
requiring hospitalization are important endpoints for
studies, as is their potential influence on worse quality
of life [14] and early and long-term outcome [6]. In the
EMBARC registry of BE patients, around one third of
them require at least one hospitalization per year [15].
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We hypothesized that several factors related to host
characteristics, to comorbidities, to prior exacerbations,
usual treatments along with BE scales must be associated
with developing exacerbations requiring hospital admission.
The aim of our study was to evaluate factors associated
with exacerbations requiring hospital admission, with
regard to host characteristics, usual treatments, severity
scores (FACED and BSI) and history of prior exacerbations,
during a one-year follow-up period.
Methods
Study protocol
We conducted a prospective, observational study of
adult bronchiectasis patients attended at the specialized
outpatient clinics of two tertiary care university hospitals
between 2011 and 2015 belonging to the Spanish Na-
tional Health Service. Inclusion criteria included a com-
patible clinical history consistent of chronic sputum
production and/or frequent respiratory infections with
confirmed findings of bronchiectasis by computerized
tomography (CT) scan of lungs performed prior to study
recruitment. The investigation of the etiology of bronchi-
ectasis was performed using a protocol in accordance to
Spanish guidelines [16]. Exclusion criteria were: a) se-
vere immunosuppression, as in solid-organ or bone-
marrow transplantation or Human immunodeficiency
virus infection/acquired immune deficiency syndrome
(HIV/AIDS), or receiving chemotherapy or other im-
munosuppressive drugs (≥20 mg prednisone-equivalent
per day for 2 weeks or more); b) active tuberculosis; c) cys-
tic fibrosis (CF); and d) pulmonary interstitial disease. Pa-
tients signed the informed consent form (Biomedical
research ethics committee Hospital La Fe 2011/0342), and
after enrolment they were followed up for 1 year.
Data collected were demographic data, diagnosis of BE,
comorbidities, smoking, alcohol intake, and vaccine status
(flu and pneumococcal vaccines). Comorbid conditions
recorded were diabetes, chronic obstructive pulmonary
disease (COPD), asthma, chronic heart failure, myocardial
infarction, prior tuberculosis, and renal, liver and cerebro-
vascular diseases. We recorded COPD as comorbidity simi-
lar to other studies [17] and we defined bronchiectasis
associated with COPD in the presence of a smoking history
of at least 10 pack-years with airflow obstruction (FEV1/
FVC ratio < 0.7) according to the Global Initiative for
Chronic Obstructive Lung Disease recommendations [18].
The association between BE and COPD is currently under
an ongoing debate regarding the difficulties in its
clarification [19–21].
Data related to previous chronic infections (defined
according to Spanish guidelines), [16] number of exacerba-
tions in the previous year, and bronchiectasis severity scores
(BSI, FACED) [6, 22] were also recorded for all patients.
Usual chronic and concomitant medications included
bronchodilators, corticosteroids, theophylline, inhaled/nebu-
lized antibiotics, proton pump inhibitors, long-term oxygen
therapy, and mucolytic drugs in the last 6 months frame.
The microbiological diagnosis of exacerbation was
performed with the following tests: sputum culture,
urine (Binax Now for S. pneumoniae and L. pneumophila
urinary antigen test), two blood samples, and nasopharyn-
geal swabs (for influenza A and B, parainfluenzae, syncytial
respiratory virus, and adenovirus). Sputum and bronchoal-
veolar lavage (BAL) were processed for Gram and Ziehl–
Neelsen strains and for cultures of bacterial, fungal and
mycobacterial pathogens. Sputum samples were considered
acceptable if there were more than 25 leukocytes and fewer
than 10 squamous cells per low-power microscope field.
Invasive samples, as BAL, were obtained only if requested
by the attending physician. In outpatients exacerbations
microbiological tests included sputum culture and any
other additional test according to physician decision. The
microbiological etiology of exacerbation was defined as any
positive result from the microbiological investigation, as per
previous publications [23].
Exacerbation definition and follow-up
In accordance with Spanish guidelines [16] exacerbations
were defined as follows: acute change in sputum
characteristics (increased volume, change of viscosity,
purulence) with or without increased dyspnea after
ruling out any other causes, along with the requirement
of a new antibiotic treatment prescribed in our specialized
clinic and/or unscheduled admission to hospital. Exacerba-
tions presenting with a new infiltrate in chest-X-ray were
also recorded. The decision of hospital admission was made
by the attending physician at emergency department with-
out pre-prepared criteria and considering acute findings
-clinical, analytical and radiographic- consistent with severe
exacerbation [16].
Inpatients were followed up in visits to the specialized
clinic at 30 days, 90 days and 1 year after discharge. For
outpatients, follow-up was performed on day 7, 30 days,
90 days and 1 year. A telephone interview was conducted
for patients who did not go to the visits to assess follow-up
outcomes.
Statistical analysis
Univariable analysis
Statistical analysis was performed using the SPSS 20.0
software program (IBM Corporation, Armonk, NY,
USA). Qualitative variables were compared using the χ2
test. Quantitative variables were analyzed using the
ANOVA test or the Kruskal-Wallis test. Values of p
≤0.05 were considered statistically significant. The total
cohort of patients was separated in two groups: the
study group comprised patients requiring one or more
hospital admission due to exacerbation during the one-
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year follow-up period, and the control group those that
did not require hospitalization.
Multivariable analysis
Two logistic regression analyses were performed to pre-
dict hospital admission during 1-year follow-up as the
dependent variable (≥1 admissions during 1 year follow-
up vs. no hospital admission). Independent variables
were the ones with p < 0.1 in the univariable analysis and
those considered clinically relevant such as comorbid
conditions and usual treatments. To address colinearity
among variables highly correlated with each other, we
used the variation inflation factor. Since both BSI and
FACED are prognostic BE scales highly correlated they
were introduce in the multivariate analysis separately;
BSI in the first model and FACED in the second. The
Hosmer and Lemeshow goodness-of-fit test was used to
evaluate the adequacy of the models [24]. The area
under the receiver-operator characteristic curve (AUC)
for the models was also calculated.
Results
Patient characteristics
The cohort consisted of 319 patients followed up for 1
year and separated in two subsets: patients treated as
outpatients and those admitted to hospital at least once
during the follow-up period (Fig. 1). The mean age for
the whole cohort was 68.4 (65 years in outpatients vs 73
in inpatients, p < 0.001); 106 (40%) were male and 159
were female. The distribution according to the FACED
scale was 133 (50.2%) mild, 89 (33.6%) moderate, 43
(16.2%) severe, and according to the BSI scale 47 (17.7%)
mild 73 (27.5%) moderate, 145 (54.7%) severe.
Three patients died during the exacerbation and 12
more in the 1-year follow up period; mortality was
higher in hospitalized patients (p: 0.04).
Risk factors for hospital admission. Clinical features of
hospitalized exacerbation
Univariable analysis
A total of 162 patients were admitted to hospital during
the follow-up period. Forty five patients had respiratory
failure, 133 worsening dyspnea, 60 new findings in chest
radiograph, 53 tachypnea ≥22, 57 tachycardia ≥100 and
51 fever ≥38 °C. Their characteristics, etiological BE
diagnosis, previous bronchial chronic infection, number
of exacerbations, number of prior antibiotic treatments,
usual concomitant medications and severity scores are
described in Table 1. Hospitalized patients were older,
with more chronic comorbid conditions but with similar
colonization rates. The median days from onset of
exacerbation to first visit was 4 days (IQR:2–10) in out-
patients (data obtained in 49 out of 70) and 3 (IQR 2–7)
in those hospitalized (data from 139 out of 162 patients),
p:0.1. Prognostic scales according to hospital admission
are shown in Fig. 2. The distribution of the etiology of
BE is shown in Table 2.
Fig. 1 Flowchart
Menéndez et al. Respiratory Research  (2017) 18:176 Page 3 of 8
Multivariable statistical analysis
Four independent risk factors and one protective
factor were identified for predicting hospital admis-
sion at 1-year follow-up in the model adjusted by BSI
score (Table 3) (FEV1, previous hospitalization due to
BE and P. aeruginosa colonization were excluded by
colinearity). Five risk factors and one protective factor
were identified in the model adjusted by FACED
score (FEV1 and P. aeruginosa colonization excluded).
The AUC was 0.799 (95% CI: 0.745–0.853) for BSI
model and 0.813 (0.760–0.866) for FACED model.
Discussion
This study identified patient characteristics and clinical
predictors of admission due to an exacerbation during a
one-year-follow up period in BE patients. Age, heart
failure, previous hospitalization due to BE, use of proton
pumps inhibitors, and BE scales (FACED and BSI) were
associated factors for hospital admission, whereas
pneumococcal vaccination was a protective factor.
Patients with BE frequently present chronic infections
by pathogens with exacerbations that may require
hospital admission, although the associated factors that
cause them are not clearly identified. The publication for
defining BE exacerbation has just been published
although it has not include criteria for hospitalization
[25]. It has been suggested that these criteria may be
similar to those of COPD [26]. Exacerbations may be
caused by pneumonic or non-pneumonic episodes that
are very difficult to distinguish in clinical practice with-
out performing a CT-scan; this is why, in our study, we
Table 1 Patient Characteristics, Comorbid Conditions, Usual
Treatments, Prior Colonization Status and Scales According to
Hospitalization
Characteristics Hospitalization at one year follow-up
No Yes p-value
Total No. 103 (38.9) 162 (61.1)
Demographic data
Age (years) 65 (55–73) 73 (68–80) <0.001
Gender
Male 27 (26.2) 79 (48.8) <0.001
Female 76 (73.8) 83(51.2)
Smoker or former smoker 48 (46.6) 77 (47.5) 0.883
Alcohol abuse 4 (3.9) 7 (4.3) 0.862
Flu vaccine 75 (72.8) 109 (67.3) 0.341
Pneumococcal vaccine 59 (57.3) 64 (39.5) 0.005
PPSV23 48 (46.6) 54 (33.3) 0.030
PCV13 11 (10.7) 10 (6.2) 0.186
Comorbid condition
Diabetes mellitus 7 (6.8) 34 (21) 0.002
Myocardial infarction 2 (1.9) 16 (9.9) 0.012
Heart failure 3 (2.9) 31 (19.1) <0.001
Dementia 3 (2.9) 6 (3.7) 0.729
COPD 11 (10.7) 54 (33.3) <0.001
Asthma 11 (10.7) 15 (9.3) 0.705
Renal disease 4 (3.9) 10 (6.2) 0.417
Liver disease 3 (2.9) 13 (8) 0.089
Radiology
Cystic bronchiectasis 6 (5.8) 11 (6.8) 0.755
Colonization
Pseudomonas aeruginosa
colonization
34 (33) 66 (40.7) 0.206
Colonization by other
microorganism
23 (22.3) 28 (17.3) 0.310
Colonization by MDR
microorganism
7 (6.8) 23 (14.2) 0.064
Treatment
Long-acting β-agonist 79 (76.7) 125 (77.2) 0.931
Long-acting anticholinergic 40 (38.8) 100 (61.7) <0.001
Inhaled corticosteroids 75 (72.8) 123 (75.9) 0.570
Long term oral antibiotics 11 (10.7) 16 (9.9) 0.833
Inhaled/Nebulized antibiotic 17 (16.5) 29 (17.9) 0.770
Mucolytics 28 (27.2) 51 (31.5) 0.456
Proton pump inhibitor 26 (25.2) 100 (61.7) <0.001
Chronic oxygen therapy 4 (3.9) 25 (15.4) 0.013
Statins 21 (20.4) 26 (16) 0.367
Regular chest physiotherapy 33 (32) 42 (25.9) 0.282
Immunosuppressors 1 (1) 4 (2.5) 0.382
NIMV 0 (0) 4 (2.5) 0.108
Table 1 Patient Characteristics, Comorbid Conditions, Usual
Treatments, Prior Colonization Status and Scales According to
Hospitalization (Continued)
Characteristics Hospitalization at one year follow-up
No Yes p-value
History of exacerbations
Hospitalization last year due to
BE
23 (22.3) 97 (59.9) <0.001
Previous hospitalization due to
BE at anytime
33 (32) 98 (60.5) <0.001
Previous history of pneumonia 39 (37.9) 85 (52.5) 0.020
Exacerbation last year 74 (71.8) 118 (72.8) 0.860
No. exacerbations last year 1 (0–2) 1 (0–2) 0.482
No. antibiotic treatments last
year >2
19 (18.4) 39 (24.1) 0.280
Data are presented as n (%) or median (interquartile range)
Alcohol abuse: More than 80 g/day
PPSV23 pneumococcal polysaccharide vaccine
PCV13 pneumococcal conjugate vaccine
COPD chronic obstructive pulmonary disease
MDR multidrug-resistant
NIMV non-invasive mechanical ventilation
P-value: The χ2 test was performed for categorical data and the Mann-Whitney
U test was performed for continuous data
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did not separate exacerbations on the basis of the
appearance of new infiltrates. In a prior study, Polverino
et al. [23] reported that BE was present in 3% of hospi-
talized community-acquired pneumonia (CAP) patients
and that on average BE patients had two or three exacer-
bations per year. Our study found that patients requiring
hospitalization were older, had more chronic diseases,
more regular concomitant treatments and higher
chronic Pseudomonas colonization.
We found five independent risk factors for exacerba-
tions requiring admission to hospital: age, use of proton-
pump inhibitors, previous BE hospitalization, heart
failure and BE scales. An important factor such as
chronic Pseudomonas colonization highly associated with
requirement of hospitalization was not evaluated in the
multivariable analysis due to the fact that it is included
in the severity scales presenting high colineality [11].
Use of proton-pump inhibitors is recognized as a risk
factor for the appearance of CAP, with a 1.5-fold
increase, [27] and for COPD exacerbation [28]. Although
the pathophysiological mechanisms have not been
clearly defined, it has been suggested that CAP may
develop due to the influence of proton-pump inhibitor
(PPIs) on the gut microbiome [29]. In fact, PPIs modify
the composition of the microbiome, reducing microbial
abundance in gut and increasing levels of oral and upper
gastro-intestinal tract commensals due to changes in
pH. This alteration of microbiome could contribute to
develop more severe exacerbations requiring hospital
admission. The con formation of this hypothesis will
require further investigations. Schuijt et al. [30] in a mouse
model found that after the depletion of the gut microbiota,
there was an increase in bacterial dissemination, inflamma-
tion and even organ damage. Purcell et al. [31] reported
that in some patients acute BE exacerbations, their
frequency, and episodes of clinical stability are correlated
with a significantly different bacterial community structure,
which is associated with the presence of particular taxa in
non-cystic fibrosis bronchiectasis.
Airway reflux is quite prevalent in BE patients [32] and it
is also a recognized risk factor for exacerbation, [33] just as
it is in hospitalized patients with moderate-to-severe COPD
Fig. 2 Distribution of subset of patients in the cohort (≥1 hospital admission vs no admissions) according to FACED and BSI scores
Table 2 Etiology of bronchiectasis and 1 year follow-up
hospitalization
Etiology of bronchiectasis
1 year follow-up hospitalization p-value
No Yes
Idiopathic 44 (42.7) 48 (29.6) 0.005
Post-infectiousa 30 (29.1) 51 (31.5)
COPDb 10 (9.7) 42 (25.9)
Others 19 (18.4) 21 (13)
Data are presented as n (%)
COPD Chronic obstructive pulmonary disease
P-value: the Mann-Whitney U test was performed for continuous data
aA diagnosis of postinfective bronchiectasis was made if the patient reported a
history of symptoms due to bronchiectasis with an onset after a severe
respiratory infection, such as pneumonia or tuberculosis, according to clinical
judgment and regardless of the latency between the event and the
occurrence of symptoms of bronchiectasis [38]
bBronchiectasis associated with COPD was diagnosed in the presence of a
smoking history of at least 10 pack-years with airflow obstruction (FEV1/FVC
ratio < 0.7) according to the Global Initiative for Chronic Obstructive Lung
Disease [20]
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[28]. In fact, symptoms of airway reflux independently
predict severity and exacerbation frequency in BE [33].
However, our findings and those of prior publications are
not sufficient to fully evaluate the impact of the disease
and/or the use of PPIs; the role of airway reflux and its
treatment with PPIs needs to be better clarified in BE
patients in larger cohorts .
Previous hospitalization was an independent risk fac-
tor for a BE exacerbation requiring hospital admission.
Prior hospitalization has been clearly identified as the
most decisive risk factor for severe exacerbation in other
chronic respiratory diseases [34]. Moreover, having been
hospitalized for an exacerbation significantly increased
the risk of mortality. Greater bronchial and systemic
inflammation has been observed during exacerbations,
[35] which probably contributes to perpetuating the
infection-inflammation cycle and has a negative effect
on prognosis. The percentage of females treated ambula-
tory was higher than males while in patients requiring
hospital there were no gender differences. Male gender
was associated with more severe disease, more comor-
bidities and higher Pseudomonas colonization similar to
other studies [36, 37]. When adjusting by these factors,
gender disappear as independent risk factor for admis-
sion. Ringshausen et al. [3]have also reported an
increased in hospitalization among elderly men.
As might be expected, BE patients with higher BSI and
FACED scores required more hospital admissions,
regardless its recognized differences in classifying BE
patients in the severe phases: -BSI classified more
patients as severe than FACED- [38, 39] as confirmed in
our study. The mathematical models retained identical
risk and protective factors with minor changes in the
OR when both scales (BSI or FACED) are evaluated
separately. Recently the new E-FACED [40] and Exa-
FACED scores [39], which incorporates the number of
exacerbations, has demonstrated a better prognostic
capacity for subsequent exacerbations and 1 year
hospitalization. Recently, McDonnell et al. defined the
Bronchiectasis Aetiology Comorbidity Index (BACI) in
an elegant study [17] based on multimorbidity and its
independent influence for mortality prediction. This
score improves predictive capacity of other scales
including the prediction for admission. Nevertheless,
this score does not include data as vaccination and/or
concomitant treatments, determinant predictors of
hospitalization in other infectious lung diseases as
CAP [41]. In our study, designed prior to publication
BACI scale, we have found the independent effect of
heart failure that is a frequent comorbid condition in
patients with chronic respiratory diseases.
Vaccination against influenza and pneumococci are
associated with better survival in patients with BE [42].
This protective factor was confirmed in exacerbations
requiring hospital admission; to our knowledge, this has
not been previously reported in BE patients. Pneumo-
coccal vaccine has been recommended in the literature
[43, 44] although specific studies for the BE population
are lacking. Although, there are no data on the influence
of vaccination on hospitalization in bronchiectasis, there
Table 3 Predictors of hospital admission: univariable and multivariable analysis
Univariable analysis Multivariable analysis
OR (95% C.I.) P-value BSI model
OR (95% C.I.)
P-value FACED model
OR (95% C.I.)
P-value
Age 1.07 (1.04–1.08) <0.001 1.01 (0.99–1.04) 0.270 1.03 (1.01–1.07) 0.021
Male 2.68 (1.57–4.58) <0.001 1.27 (0.57–2.82) 0.559 0.16 (0.53–2.54) 0.702
Pneumococcal vaccine 0.49 (0.29–0.80) 0.005 0.37 (0.19–0.70) 0.003 0.40 (0.21–0.74) 0.004
Diabetes Mellitus 3.64 (1.55–8.57) 0.003 1.62 (0.60–4.76) 0.355 1.57 (0.59–4.55) 0.380
Myocardial infarction 5.53 (1.24–24.60) 0.025 0.78 (0.14–6.92) 0.794 0.72 (0.13–6.06) 0.727
Heart failure 7.89 (2.34–26.54) 0.001 6.31 (1.55–43.07) 0.023 5.47 (1.36–37.23) 0.035
COPD 4.18 (2.06–8.47) <0.001 2.06 (0.79–5.63) 0.145 2.42 (0.93–6.59) 0.074
Previous MDR colonization 2.27 (0.94–5.50) 0.070 0.97 (0.32–3.10) 0.956 1.16 (0.40–3.61) 0.791
Long-acting anticholinergic 2.54 (1.53–4.22) <0.001 1.48 (0.74–2.92) 0.262 1.69 (0.87–3.30) 0.120
Proton pump inhibitor 4.78 (2.77–8.24) <0.001 2.64 (1.35–5.26) 0.005 2.85 (1.48–5.59) 0.002
Chronic oxygen therapy 4.52 (1.52–13.39) 0.007 1.82 (0.46–9.47) 0.427 2.73 (0.70–14.05) 0.179
Previous hospitalization due to BE at any time 3.25 (1.93–5.46) <0.001 – – 2.63 (1.36–5.17) 0.005
Previous history of pneumonia 1.81 (1.095–3.00) 0.021 1.55 (0.81–2.99) 0.185 1.41 (0.73–2.75) 0.307
FACED 5.22 (2.97–9.20) <0.001 – – 0.97 (0.78–1.22) 0.810
BSI 13.79 (6.53–29.13) <0.001 1.20 (1.09–1.32) <0.001 – –
BE Bronchiectasis, BSI Bronchiectasis severity index, FACED F-FEV1, A-Age, C-Pseudomonas aeruginosa colonization, E-extension and D-Dyspnea, C.I. Confidence
interval, COPD Chronic obstructive pulmonary disease, MDR Multidrug-resistant, OR Odds ratio
Menéndez et al. Respiratory Research  (2017) 18:176 Page 6 of 8
is evidence of its influence on the occurrence of
exacerbations [45].
Exacerbations admitted to hospital increased the risk of
death during the study period compared with non-
hospitalized exacerbations. Thereafter, an important aim
should be to reduce the frequency and severity of exacer-
bations [46]. Severe exacerbations cause increased local
and systemic inflammation, and repeat exacerbations
probably contribute to a persistent cycle of inflammation
and infection, with negative consequences for prognosis.
In fact, after hospital admission, there were increases in
both the percentage of new exacerbations at 30 days and
mortality in the following year.
Our study has a number of limitations that should be
mentioned. First, it is difficult to evaluate the presence of
new infiltrates in BE exacerbations as pneumonia or merely
exacerbation without performing a CT-scan. Our study was
designed to follow our cohort in a “real life scenario”, that
is, with chest X-rays instead of CT-scans, which are not
feasible in a disease with frequent exacerbations. Our
patients were recruited from specialized BE clinics
representing a subset of patients with more advanced
phases therefore our findings could not be generalizable for
milder BE populations.
Conclusion
In summary, our study identified a group of vulnerable BE
patients likely to develop exacerbations requiring
hospitalization during a one-year follow-up period adding
some new valuable additional information to validated
scales. These BE patients would probably benefit from a
more extensive follow-up, high quality specialized care,
intensified treatment, vaccine implementation and even
novel therapies in order to improve prognosis. Identifica-
tion of risk factors associated with hospital admission and
more studies regarding the role of PPIs; may help to devise
preventive strategies for improving the course of the disease
and reducing both morbidity and the economic burden.
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